The ophthalmic packaging market will grow from USD 11.42 billion in 2025 to USD 23.65 billion by 2034, at a CAGR of 8.43%. The rising cases of eye diseases such as cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy are driving the need for safe and effective packaging that keeps medicines secure and ensures accurate use.
Ophthalmic Packaging Market Top Companies
- Gerresheimer AG
- AptarGroup, Inc.
- Amcor Plc
- Schott AG
- Berry Global Inc.
- West Pharmaceutical Services, Inc.
- Bormioli Pharma
- Nolato AB
- Catalent, Inc.
- Nemera
- RPC Group Plc (Berry Global)
- Tekni-Plex
- Nipro Corporation
- Albea Group
- DWK Life Sciences
- SGD Pharma
- Silgan Holdings
- Origin Pharma Packaging
- RxPack
- Raepak Ltd
Latest Announcements By Industry Leaders
- In June 2025, Torrent Pharmaceuticals revealed that it had acquired the majority stake in JB Chemicals and Pharmaceuticals in an Rs 19,500-Crore deal, which will make it the second most valued pharmaceutical company in India.
- In March 2025, TC Biopharm officially signed a non-binding letter of intent to gain an ophthalmic pharmaceutical organisation concentrating on commercialising intraocular pressure-lowering therapies for patients with ocular hypertension and glaucoma. The goal organisations have a US Food and Drug Administration-approved one-time-a-day eye drop which lowers intraocular pressure, and a growth-stage asset pipeline in ophthalmology indications.
- In December 2024, Gerresheimer, an inventive solution and systems provider and worldwide partner for the biotech, pharma, and cosmetic industries, completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group. The profile of the pharmaceutical company is being created using glass and plastic, as well as closure solutions.
Recent Developments
- In August 2025, Aptar Pharma revealed a major development in sustainable pharmaceutical packaging with its Freepod nasal spray pump now being manufactured with high balance bio-based resins.
- In July 2025, Worldwide pharma main company Lupin Limited revealed the launch of Loteprednol Etabonate Ophthalmic suspension of 0.5% in the United States. Lotepredonal Etabonate Suspension of 0.5% is identical to Lotemax Ophthalmic Suspension, of Bausch and Lomb.
- In April 2025, Akums Drugs and Pharmaceutical Ltd, which is India's Top contract development and manufacturing organization, disclosed the launch of cutting-edge Ripasudil-Timolol combination therapy for glaucoma diagnosis. This DCGI examined the product that displays a main growth in ophthalmic care, with Akums becoming the initial Indian CDMO to receive this inventive formulation.
